Comparison study between bacteriological aetiology and outcome of VAT & VAP  by Kahlil, Nasr H. et al.
Egyptian Journal of Chest Diseases and Tuberculosis xxx (2016) xxx–xxxContents lists available at ScienceDirect
Egyptian Journal of Chest Diseases and Tuberculosis
journal homepage: www.sciencedirect .comComparison study between bacteriological aetiology and outcome
of VAT & VAPhttp://dx.doi.org/10.1016/j.ejcdt.2016.10.008
0422-7638/ 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer review under responsibility of The Egyptian Society of Chest Diseases and
Tuberculosis.
⇑ Corresponding author.
E-mail addresses: hanaamohammedali@gmail.com (N.H. Kahlil), amanytodary@
gmail.com (A.T. Khalil), Dalal1959@yahoo.com (D.E. Abdelaal).
Please cite this article in press as: N.H. Kahlil et al., Comparison study between bacteriological aetiology and outcome of VAT & VAP, Egypt. J. Ch
Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcdt.2016.10.008Nasr H. Kahlil a,⇑, Amany Todary Khalil b, Dalal ElSayed Abdelaal c
aAhmed Maher Teaching Hospital, Cairo, Egypt
bChest Department, Ain Shams University Hospital, Cairo, Egypt
cClinical Pathology Department, Ain Shams University, Cairo, Egypt
a r t i c l e i n f o a b s t r a c tArticle history:
Received 4 September 2016
Accepted 19 October 2016
Available online xxxx
Keywords:
VAT
VAPMechanical ventilation (MV) is a life saving process but it carries risks of respiratory tract infection as
ventilator associated tracheobronchitis (VAT) and ventilator associated pneumonia (VAP) leading to
increase morbidity and duration of mechanical ventilation in intensive care unit (ICU). VAT is an interme-
diate stage between colonization and VAP.
Aim of the work: To compare between VAT and VAP as regards microbiological diagnosis and outcome of
patients.
Subjects and methods: The current study includes twenty patients admitted to respiratory ICU with res-
piratory failure developed VAT and VAP after 48 h of MV and to evaluate their impact on patient’s out-
come.
Results: Klebsiella was the commonest organism in both groups and that duration of stay on MV was
observed in VAT patients and most of VAT patients progressed to VAP.
Conclusion: From the study we concluded that VAT infection is as severe as VAP and it needs more atten-
tion to prevent its presence as, once present, it usually progress to VAP increasing mortality rate in ICU.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Mechanical ventilation is life saving process but it carries risks
of VAT and VAP which are associated with increase morbidity,
duration of MV and mortality in ICU. VAT is believed to be an inter-
mediate stage between colonization of the lower respiratory tract
and VAP. However VAT may be a separate entity that may con-
tribute to increase length of ICU stay and duration of MV Both
VAP & VAT are clinically characterized by presence of fever,
mucopurulent bronchial secretions & leukocytosis. In contrast to
VAP, VAT does not involve pulmonary parenchyma and as a result
does not cause radiographic pulmonary infiltrates. Accurate diag-
nosis of VAT is challenging as many conditions commonly encoun-
tered in critically ill patients can mimic its signs & symptoms [1].Aim of the work
To document practice of clinical & microbiological diagnosis of
VAT & VAP and to evaluate the impact of VAT & VAP on patient’s
outcome.
Subjects and methods
The study included twenty patients admitted to respiratory I.C.
U suffering from respiratory failure and mechanically ventilated.
Exclusion criteria
- Patients with ongoing nosocomial infection.
- Pregnant women.
- Patients with community acquired pneumonia.
- Patients with neutropenia <1000WBC/mm3.
All patients were subjected to:
- Full history taking, general and local chest examination.
- Lab investigations (ABG, CBC and Renal function tests).est Dis.
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daily assessment of
- patients as regards:
1. Tracheal secretions quantity and character (Volume of secre-
tions was graded according to the following scale: Scanty
<30 ml/day and profuse >100 ml/day).
2. Temperature
3. PaO2/FIO2 twice weekly
4. Assessment of chest X-ray twice weekly
5. Leukocytic count
- Microbiological assessment by quantitative culture of respira-
tory secretion by Mini-BAL maneuver to take samples from
lower respiratory tract.
Mini-BAL sampling was done at the first day of mechanical ven-
tilation and after 48 h of mechanical ventilation.
Patients with positive culture after 48 h were included in the
study. Patients were divided into two groups; group I (VAT) group
II (VAP).
VAT diagnosed according to the following criteria:
Patient has no clinical or radiological evidence of pneumonia
and has two of the following signs and symptoms in absence of
other obvious cause:
- Fever (temp > 38 C or < 36 C).
- Leucocytosis > 12.000/mm3.
- Sputum production; increase amount and change of color to
yellow, greenish or pus.
- Positive cultures obtained by mini-BAL catheter (We used <103
as cut off value of colony count for positive culture for diagnosis
of VAT. For diagnosis of VAP we used the same criteria for diag-
nosis of VAT with the development of CXR shadow suggestive of
pneumonia, which equal to CPIS score >6 and we used 103 as
cut off value of colony count for diagnosis of VAP) [2].
Mini- BAL technique
Materials used
a. Nelaton catheter size (18-FG), its distal end was cut and used
as outer protective catheter.
b. Infant rhyle catheter size (10-FG) was used as the inner
catheter and sterile K-y gel was used to block the distal
end of the outer catheter.
c. Sterile gloves and 3 syringes 20 ml each of normal saline and
a specimen container.
Procedure
According to Abd ElFattah et al.,[3] the Nelaton catheter used as
outer catheter, was gently advanced into the endotracheal tube
until resistance is met, indicating that the catheter is wedged into
the distal airway, then retracted 4–5 cm. The infant rhyle catheter
is advanced in a telescopic manner through the outer catheter
extruding the K-y gel plug.
- A 20 ml syringe was connected to the inner catheter to admin-
ister its content of normal sterile saline that was aspirated again
using the same 20 ml syringe while maintaining the catheter
position. Aspiration process repeated until an appropriate spec-
imen is obtained.
- The sample was poured into specimen container carefully to
avoid contamination and close the lid tightly. Both catheters
were removed together from the airways.
- Good closed suctioning of patient’s airway was done.Please cite this article in press as: N.H. Kahlil et al., Comparison study betwee
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- All identified microorganisms were reported with their antibi-
otic sensitivities.
Bacterial culture and colony count
1. A 0.01 ml sterile calibrated loop was placed into the respective
specimen and then onto the center of three media plates (blood
agar, chocolate agar, and macconkey agar).
The media plates were then streaked using the pin wheel streak
method and incubated at 35 C.
Stained films from bacterial growth were examined by micro-
scopy for the type of bacteria, Gram reaction (Gram-positive
or Gram-negative) and morphology of the bacteria (cocci, diplo-
coccic, rods or coccobacilli).
2. Bacterial culture growth was quantitated according to the num-
ber of colonies observed per plate were counted as follows:
<10 colonies per plate represented <103 cfu / ml.
10–100 colonies per plate represented 103–104 cfu/ml.
100–1000 colonies per plate represented 104–105 cfu/ml.
1000 colonies per plate represented >105 cfu/ml.
All identified microorganisms were reported with their antibi-
otic sensitivities.
Results
Clinical criteria were as follows
- Group I:10 VAT patients received systemic antibiotics (100%)
had colored secretions, 60% were profuse in amount, 40% were
scanty, the mean temp. was (37.87 ± 0.47) the mean leucocytic
count was (14.18 ± 5.04)  103/ml the mean PaO2/FIO2 was
(166.75 ± 39.9) and no patient has CXR shadows suggesting
VAP (0%).
- Group II:
10 VAP patients received systemic antibiotics(100%) had col-
ored secretions, 30% were profuse, 70% were scanty, the mean
temp. was (37.9 ± 0.69) C the mean leucocytic count was
(13.91 ± 6.47)  103/ml, PaO2/FIO2 ratio was (166.20 ± 38.21)
and the presence of CXR shadows suggestive of VAP were in
(100%) of patients.
No significant difference between group I and group II on
admission as regards clinical criteria (in comparing; secretion
amount (p = 0.234), temperature(p = 0.542) and Leucocytic count
(p = 0.457), and in comparing PaO2/FIO2 (p = 0.65) (see Table 1).
The microbiological distribution of the micro organisms at day
1(Tables 2–5) showed that the commonest bacteria isolated from
group I was klebsiella (60%) and from group II was klebsiella (90%).
Clinical outcome after 7 days of MV
Group I (VAT) showed that secretions were still colored in all
patients, the amount decreased in 6 patients (60%), 4 patients
(40%) had profuse amount . and group II (VAP), secretions were
also still colored in all patients (100%) their amount decreased in
4patients (40%), 6patients (60%) had profuse amounts (Tables 7
and 8) and there was no significant difference between group I
and group II as regards secretion outcome (p = 0.337) (see Table 6).
As regards temperature, group I showed that 4 patients (40%)
had normal temperature 6 patients (60%) had high temp. with
mean temp (37.75 ± 0.77)and group II showed 5 patients (50%)
had normal temp. and 5 patients (50%) had high temp. with mean
temp. (37.8 ± 1.23) C. There was no significant difference betweenn bacteriological aetiology and outcome of VAT & VAP, Egypt. J. Chest Dis.
Table 1
Clinical criteria of VAT patients (group I) and VAP patients (group II).
Secretions Group I VAT Group II VAP P value
No % No %
Color 100% are colored
Colored 10 100 10 100 No needs for comparison
Not colored 0 0
Amount 0.234
Scanty 4 40 7 70 >0.05
Profuse 6 60 3 30 NS
Temp. 37–38.5 0.542
Mean 37.87 ± 0.4 >0.05
Normal < 38oc 4 40 5 50 NS
High > 38oc 6 60 5 50
Leucocytic count 0.457
<12,000 3 30 5 50 >0.05
>12,000 7 70 5 50 NS
Poa2/ FIO2 137–255 91–217.5 0.65
(166 ± 39.9) (166.20 ± 38.21) NS
CXR 0 0 10 10
Table 2
Isolated bacteria from VAT patients and their colony count.
Colony count VAT pts.
No %
Klebsiella 103 6 60%
MSSA staph aureus >104 1 10%
MRSA P105 1 10%
Pseudomonas >106 1 10%
E. coli P104 1 10%
This table shows that the commonest bacteria isolated in VAT group were klebsiella
(60%).
Table 4
The bacteria isolated from VAP patients and their colony count.
Colony count VAP pts.
No 10%
Staph aureus
<103 0 0
>104 0 0
103 0 0
105 0 0
MRSA
P105 0 0
103 0 0
104 1 10
Klebsiella
<103 0
P104 0
>105 3 30
>106 4 40
103 2 20
104 0
105 0
Acinetobacter
>104 0 0
>105 0 0
103 0 0
104 0 0
Pseudomonas
<103 0 0
>106 0 0
E. coli
P103 0 0
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(Table 9).
As regards total leucocytic count group I showed 5 patients
(50%) had normal leukocytic count and 5 patients (50%) had high
leukocytic count with mean count (13.15 ± 8.38)  103/ml . group
II showed 4 patients (40%) normal leukocytic count and 6patients
(60%) had high leucocytic count and mean leucocytic count
(15.36 ± 7.99)  103/ml .There was no significant difference
between group I and group II as regards leukocytic count outcome
(p = 0.722) (Table 10).
Regarding PaO2 /FIO2 ratio in group 1 was (150.77 ± 34.56) and
in group II was (160.89 ± 69.29). There was no significant differ-
ence between group I and group II as regards PaO2 /FIO2 outcome
(p = 0.65) (Table 11).Table 3
Distribution of the drug sensitivity for bacteria isolated in VAT patients.
Sensitivity MSSA Klebsiella Acinetobacter Pseudomonas E. coli MRSA
Aminoglycosides 1 3 1
In combination
In combination 0
Quinolones 0 0 In combination In combination 0
B. lactam 1 4 1
In combination
In combination In combination 0
Carbapenem 0 5 0 0 0 0
Tazobact/pip sulbactam/cefiperazone 0 0 1 0 0 0
Macrolides 0 2 0 In combination 0 0
Doxycyclines 1 1 1 0 0 0
Vancomycine 0 0 0 0 0 1
As regard drug sensitivity of the bacteria isolated from VAT patients were (MSSA) were sensitive to aminoglycosides, blactam, doxycycline, MRSA was sensitive to
vancomycin.
Klebsiella was sensitive to carbapenemc, B. lactam, aminoglycosides, macrolides, doxcycline. Acinetobacter was sensitive to Sulbactam /Cefiperazon + tazobactam /piper-
acillin, aminoglycosides & B. lectan in combination.
Pseudomonas was sensitive to B. lactam, quinolones, macrolides. E. coli was sensitive to aminoglycosides, quinolones and B. lactam.
>106 1 10
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Table 5
Distribution of the drug sensitivity for bacteria isolated from VAP patients.
Sensitivity MRSA (1) Klebsiella (9) Acinet 0 Pseudomonas E. coli (1) MASA
Aminoglycosides 0 2 (22%) 0 0 0 0
Quinolones 0 1 (11%) 0 0 0 0
B. lactame 0 0 0 0 0 0
Carbapenem 1 (100%) 5 (55%) 0 0 0 0
Tazobactam/piperacillin 0 0 0 0 0 0
Macrolids 0 0 0 0 0 0
Doxycyclines 0 0 0 0 0 0
Targocid 0 0 0 0 0 0
As regard drug sensitivity of the bacteria isolated from VAP pts were 55% of Klebsiella was sensitive to carbapenem followed by aminoglycosides (44%) and (11%) was
sensitive to quinolones. E. coli was resistant to all antibiotics.
Table 6
Distribution of systemic antibiotics administered to the study group.
Group I 10 pts. Group II 10 pts.
No % No %
Amikacin 2 20 6 60
Ceftazidine 5 50 6 60
Meropenam 1 10 3 30
Vancomycin 1 10 2 20
Imipenem 3 30 5 50
Levofloxacin 5 50 3 30
Cipro 5 50 4 40
Piperacillin/Tazo 5 50 3 30
Ceftriaxone 3 30 3 30
Clindamycin 1 10 2 20
Cefepime 4 40 3 30
Azithromycin 4 40 1 10
Sulperazon 1 10 2 20
Doxycyclines 0 0 1 10
Table 7
Comparison between groups as regards color of secretion.
Color of secretion Group I Group II P value
No % No %
Colored 10 100 10 100 100% are colored
Not colored 0 0 0 0 No needs for comparison
Table 9
Comparison between groups as regards temperature.
Temp. Group I Group II P value
No % No %
Range 37–39
37.75 ± 0.72
36–40
37.8 ± 1.23
0.827
>0.05
NSNormal 4 40 5 50
High 6 60 5 50
Table 8
Comparison between groups as regards secretion amount.
Amount Group I Group II P value
No % No %
Scanty 6 60 4 40 0.337
>0.05
NS
Profuse 4 40 6 60
Scanty amount <30 ml Profuse amount >30 ml
Table 10
Comparison between groups as regards Leukocytic count.
Leukocytic count Group I Group II P value
No % No %
Range X103/ml
(Mean ± SD) X103/ml
4.9–27
13.15 ± 8.38
8.4–34
15.36 ± 7.99
0.722
>0.05
NS
Normal 5 50 4 40
High 5 50 6 60
Normal WBCs 4000–11.000 c/um3
Table 11
Comparison between groups as regards PaO2/FIO2 ratio.
PaO2/FIO2 ratio Group I Group II P value
Range
(Mean ± SD)
105–202
151.27 ± 33.77
74.4–280
160.89 ± 69.29
0.65
NS
Table 13
Comparison between both groups as regards mortality.
Outcome Group I Group II P value
Died 6 60% 7 70% 0.662
>0.05
NS
Survived 4 40% 3 30%
Causes of death Septic shock (2)
ARDS (2)
Cardiac arrest (1)
Cerebral infarction
(1)
Septic shock (1)
ARDS (2)
Cardic. arrest (2)
Bilateral
pneumothorax (1)
Pulmonary
embolism (1)
0.754
>0.05
NS
Table 12
Comparison between groups as regards MV days & ICU stay.
Outcome Group I Group II P value
Range (Mean ± SD) Range (Mean ± SD)
MV days 4–49 19.80 ± 13. 8 7–30 16 ± 15.2 0.241 NS
0.91 NSICU stay days 7–51 20.7 ± 14.9 7–54 21.8 ± 13.2
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(30%) didn’t.
As regards total MV days, the average for group I was
(19.80 ± 13.83) days and for group II was (16.30 ± 5.21) days. TherePlease cite this article in press as: N.H. Kahlil et al., Comparison study betwee
Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcdt.2016.10.008was no significant difference between group I and group II as
regards MV days (p = 0.241) (Table 12).
As regards total ICU stay days, for group 1 was (20 ± 4.9) days
and for group II was (21.8 ± 13.2) days. There was no significant
difference between group I and group II as regards ICU stay days
(p = 0.910) (Table 12).
As regards mortality group 1, 6 patients (60%) died, while 4
patients (40%) discharged and in group II 7 patients (70%) died
and 3(30%) patients discharged. There was no significant differencen bacteriological aetiology and outcome of VAT & VAP, Egypt. J. Chest Dis.
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Causes of death in group I were septic shock, ARDS (20% for each
of them), cardiac arrest, cerebral infarction (10% for each of them).
Group II: ARDS and cardiac arrest (20% for each of them) septic
shock, bilateral pneumothorax and pulmonary embolism (10% for
each) (Table 13).Discussion
Bronchitis and pneumonia are the most common hospital
acquired infections in ICUs[4]. Ventilator associated pneumonia
(VAP), remains the intensive care unit (ICU) infection associated
with the highest morbidity and mortality and ventilator associated
tracheobronchitis (VAT) is considered an intermediate condition
between bacterial colonization and VAP. VAT and VAP have similar
clinical presentations and microbiological diagnostic criteria,
except that VAP requires a new and persistent infiltrate on chest
X-ray [5].
IN the present study there was no significant difference
between group I and group II on admission as regards clinical cri-
teria (in comparing; secretion amount (p = 0.234), temperature
(p = 0.542) and Leucocytic count (p = 0.457), and in comparing
PaO2/FIO2 (p = 0.65).
VAT & VAP are caused by a wide range of bacterial pathogens,
due to leakage around the endotracheal tube cuff or at time of intu-
bation [6].
In the present study, the clinical criteria for diagnosis of VAT are
matching with Nseir et al. [7] who studied the effect of developing
VAT on outcome of 55 patients without chronic respiratory failure
and also with Nseir et al. [8], study about the effect of antimicrobial
treatment for VAT patients. on their outcome where VAT was iden-
tified by using certain criteria including fever >38 C, new or
increase sputum production positive endotracheal aspirate culture
P106 cfu/ml and no radiological evidence of nosocomial
pneumonia.
In addition, the clinical criteria of VAT in the current study agree
with Craven et al. [9], who followed up 188 mixed ICU patients
intubated for >48 h for getting VAT or VAP by at least 2 clinical cri-
teria (fever, leucocytosis or purulent sputum) for diagnosis of VAT
plus persistent infiltrates for diagnosis of VAP.
In the present study the microbiological distribution (Tables 2–
5) showed that the commonest bacteria isolated from group I was
klebsiella (60%) and from group II was klebsiella (90%).
The microbiological criteria of the present study matches with
Papazian et al. [10] who assessed the diagnostic accuracy of bron-
choscopic techniques (BAL, PSB), and non bronchoscopic tech-
niques (BBS and mini BAL) in the diagnosis of VAP and used
103 cFu/ml as the threshold of positivity for cultures obtained with
mini- BAL samples and also matches with Josph Maria et al. [11]
who compared the quantitative culture with the microscopic.
examination of intracellular organisms of mini BAL samples for
diagnosis of VAP & used positive quantitative cultures of the sam-
ples obtained by mini-BAL >103 cfu/ml. in addition the current
study matches with Herve et al. [12] study who compared sam-
pling methods; blind tracheal aspirate, blind protected telescopic
catheter (mini:BAL technique) and bronchoscopic protected cathe-
ter for the diagnosis of VAP and had shown that the best threshold
for blind protected telescopic catheter (mini- BAL) was between
(102 and 103 cfu/m).
As regards drug sensitivity in the current study; klebsiella was
sensitive to cabapenam, Aminoglycosides Macrolides, Acintobacter
was sensitive to sulbactam (Cefiperazonet/Tazobactan/piperacillin,
aminoglycosides, and B. Lactam. Pseudomonas was sensitive to B.
lactain., Quinolones, Macrolides. E. Coli was sensitive to Aminogly-
cosides, Quinolones & to B. lactan.Please cite this article in press as: N.H. Kahlil et al., Comparison study betwee
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[13] who reported that Gram negative organisms were the most
frequent isolates from VAT patients but pseudomonas was the
highest percentage in their studies while i The current work also
matches with that done by Dallas et al. [1] who found that
Gram-ve organisms were the commonest organisms, of VAT pat-
ints, in addition, the present study agree with study done by Mar-
tin Loeches et al. [14] who also reported that VAT was frequently
caused by Gram-negative bacteria, Pseudomonas, Acinetobacter
Staph aureus, and also infection was polymicrobial in some
patients with VAT. Also Carvent et al. [9] was similar to our study
who found that Gram negative bacteria were the most frequent
organisms isolated.
The current work agrees with the work done by Dallas et al. [1],
and revealed that Gram negative bacteria were the commonest
(64%) in VAP patients. Pseudomonas aeruginosa was the common-
est (12.2%) Gram positive organisms accounted for (27.8%) and
infection was polymicrobial in (19.3%) of patients. As regards
amount, color of secretion, leucocytic count there was no signifi-
cant difference between both groups in day 1 & day 5. As regard
M. ventilator days and ICU stay there was no significant difference
between Group I & Group II. Also as regard mortality rate and cause
of death there was no significant difference between both groups.
In the present study there was no significant difference
between group I and group II as regards secretion outcome
(p = 0.337), or between group I and group II as regards temperature
outcome (p = 0.827) (Table 9), or between group I and group II as
regards leukocytic count outcome (p = 0.722) (Table 10) and no
significant difference between group I and group II as regards
PaO2/FIO2 outcome (p = 0.65) (Table 11).
Seven VAT patients (70%) in the present study progressed to
VAP and 3 patients (30%) didn’t progress to VAP.
As regards total ICU stay days in the present study; for group 1
was (20 ± 4.9) days and for group II was (21.8 ± 13.2) days. There
was no significant difference between group I and group II as
regards ICU stay days outcome (p = 0.910) (Table 12).
Regarding mortality in the current study; group I: 6 patients
(60%) died, while 4 patients (40%) discharged and in group II 7
patients (70%) died and 3(30%) patients discharged. There was no
significant difference between group I and group II as regards mor-
tality (p = 0.662). Causes of death in group I were septic shock,
ARDS (20% for each of them), cardiac arrest, cerebral infarction
(10% for each of them). Group II: ARDS and cardiac arrest (20%
for each of them) septic shock, bilateral pneumothorax and pul-
monary embolism (10% for each) (Table 13).
In accordance with our study, in a prospective observational
Cohort study by Craven et al. [15] of medical and surgical ICU
patients, VAT was associated with increase length of ICU stay, more
mechanical ventilator days, higher mortality in medical than surgi-
cal ICU patients. Nseir et.al. also demonstrated that appropriate
antibiotic treatment was independently associated with decrease
risk of transition from VAT to VAP [16].
There is increasing interest in using intravenous ± aerosolized
antibiotics delivered by improved neubulizers, placed in the venti-
lators circuit, to treat more virulent organism, drug resistant
pathogens such as staph aureus, p. aerugniosa and klebsiella pneu-
monia, aerosolized antibiotics therapy can deliver higher doses of
antibiotics to the lung parenchyma that is not absorbed systemi-
cally & therefore decreased risk of Clostridium difficile infection
[17].Conclusion
From this study we concluded that, VAT infection is as severe as
VAP and it needs more attention to prevent its presence as, oncen bacteriological aetiology and outcome of VAT & VAP, Egypt. J. Chest Dis.
6 N.H. Kahlil et al. / Egyptian Journal of Chest Diseases and Tuberculosis xxx (2016) xxx–xxxpresent, it usually progress to VAP increasing mechanical ventila-
tion days, ICU stay days and mortality rate in ICU.References
[1] J. Dallas, L. Skrupky, W.A. Boyle III, M.H. Kollef, Ventilator associated
tracheobronchitis (VAT) in a mixed surgical & medical ICU population, Chest
139 (2011) 513–518.
[2] T.C. Horan, M. Andrus, M.A. Dudeck, CDc/NHSN: surveillance definition of
health care associated infection and criteria for specific types of infections in
the acute care setting, Am. J. Infect. Control 36 (2008) 309–332.
[3] N. Abd ElFatah, A. Madkour, S. SharKawy, G. Fahumy, The efficiency of a new,
cheap & safe method in a acquiring a mini BAL sample for VAP diagnosis: an
initial Egyptian trail, Chest 134 (4) (2009) 82–83.
[4] Robert Beaglehole, Jim Kim, Paulo Teixeira, Report. Changing History, World
Health Organization, 2004, pp. 120–124, ISBN 92-4-156265.
[5] P.E. Grgurich, J. Hudcova, V. Lei, et al., Diagnosis of ventilator associated
pneumonia controversies and working toward a gold standard, Curr. Opin.
Infect. Dis. 26 (2013) 140–150.
[6] American Thoracic Society and Infectious diseases Society of America,
Guidelines for the management of adults with hospital acquired, ventilator
associated, and health care associated pneumonia, Am. J. Respir. Crit. Care
Med. 171 (4) (2005) 388–416.
[7] S. Nseir, DiPom peoc, S. Soubrier, et al., Effect of Ventilator associated
tracheobronchitis on outcome in patients without chronic respiratory failure, a
case control study, Crit. Care 9 (2005) 238–245.Please cite this article in press as: N.H. Kahlil et al., Comparison study betwee
Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcdt.2016.10.008[8] S. Nseir, R. Favory, Antimicrological treatment for ventilator associated
tracheobronchitis: a randomized, controlled multicenter study, Crit. Care
(2008) 238–245.
[9] D.E. Craven, Y. Lei, R. Ruthazer, et al., Incidence and outcome of ventilator
associated tracheobronchitis and pneumonia, Am. J. Med. 126 (2013) 542–549.
[10] L. Papazian, P. Thomas, L. Garbe, Thirion X. GuignonI, et al., Bronchoscopic or
blind sampling technique for the diagnosis of ventilator associated
Pneumonia, Am. J. Respir. Crit. Care Med. 152 (1995) 198–291.
[11] Josep Maria, L. Vidaur, S. Gonzalex, Castvop, J. deBatlle, A. Castro, A. Bonet,
Microscopic examination of intra cellular orgnisms in protected broncho alveo
mini lavage luid for the diagnosis of ventilator associated pneumonia, Chest
123 (2003) 518–523.
[12] Herve. Mentec, L. May-Michelangeli, A. Rabbat, E. Varon, Le. TurduF, G.
Bleichner, Blind and Bronchoscopic sampling methods in suspected ventilator
associated pneumonia, Intensive Care Med. 30 (7) (2004) 1319–1326.
[13] S. Nseir, F. Ader, H. Marquettec, Nosocomial tracheobronchitis, Curr. Opin.
Infect. Dis. 22 (2) (2009) 148–153.
[14] I. Martin-Loeches, S. Nseir, J. Valles, A. Artigas, From ventilator associated
tracheobronchitis to ventilator associated pneumonia, Reanimation 22 (2013)
231–239.
[15] D.E. Craven, J. Hudova, J. Rashid, Antibiotic therapy for ventilator associated
tracheobronchitis: a standard of care to reduce pneumonia morbidity and
costs?, Curr Opin. Pulmonary Med. 21 (2015) 250–259.
[16] S. Nseir, I. Martin-Loeches, D. Makris, E. Jaillete, M. Kar Younairis, Yalles, et al.,
Impact of appropriate antimicrobial treatment on Transition from VAT T VAP,
Crit. Care 18 (2014) R129.
[17] Q. Lu, R. Luo, L. Bodin, et al., Efficacy of high-dose nebulized colistin in
ventilator-associated pneumonia caused by multidrug resistant Pseudomonas
asruginosa and A cinetobacter, Authesiology 117 (2012) 1335–1347.n bacteriological aetiology and outcome of VAT & VAP, Egypt. J. Chest Dis.
